Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Overview C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Companies Involved in Therapeutics Development Dompe Farmaceutici SpA Syntrix Biosystems Inc Vaccibody AS C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Drug Profiles DF-2755A - Drug Profile Product Description Mechanism Of Action R&D Progress ladarixin - Drug Profile Product Description Mechanism Of Action R&D Progress PAC-G31P - Drug Profile Product Description Mechanism Of Action R&D Progress reparixin - Drug Profile Product Description Mechanism Of Action R&D Progress SX-517 - Drug Profile Product Description Mechanism Of Action R&D Progress SX-576 - Drug Profile Product Description Mechanism Of Action R&D Progress SX-682 - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Melanoma - Drug Profile Product Description Mechanism Of Action R&D Progress C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Dormant Products C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Discontinued Products C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Product Development Milestones Featured News & Press Releases Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer Oct 01, 2014: Dompe commitment in oncology against cancer stem cells Sep 25, 2013: Pharmaceutical company Dompé launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation Jul 10, 2013: Dompé announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true Dec 06, 2012: Dompé Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium Oct 23, 2012: Dompé Announces Enrollment Of First Patient In Phase III Trial On Reparixin Oct 24, 2011: Dompé Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress Oct 13, 2011: Dompé's Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indication, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Dompe Farmaceutici SpA, H2 2017 Pipeline by Syntrix Biosystems Inc, H2 2017 Pipeline by Vaccibody AS, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Discontinued Products, H2 2017 List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

Dompe Farmaceutici SpA Syntrix Biosystems Inc Vaccibody AS